Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 10, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies…
Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline
- Accelerated Clinical Development Expected to Enable Three Investigational New Drug/Clinical Trial Applications Within Next Three Years, Including for Familial Hypercholesterolemia as early as 2022,…
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies
iECURE to License Precision’s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to…
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio DURHAM, N.C. , NEW YORK & LONDON --(BUSINESS…
Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 25, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies…
Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update
- Presented Interim Data Showing PBCAR0191 with Enhanced Lymphodepletion Yielded Overall Response Rate of 75% and Complete Response Rate of 50% at Day ≥ 28 - Dosed First Patient in CD19-Targeted…
Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 5, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies…
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 1, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies…
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
DURHAM, N.C. & STAMFORD, Conn. --(BUSINESS WIRE)--Jun. 28, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene…
Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma
Company Reports Updated Phase 1/2a Interim Study Results for 12 R/R Non-Hodgkin Lymphoma Patients who Received PBCAR0191 CAR T Cells Following Enhanced Lymphodepletion (eLD) - Median Interval of 1…
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo
Learnings to be Presented by Carlos Moraes , Ph.D., from University of Miami at UMDF’s Mitochondrial Medicine Symposium on June 4, 2021 DURHAM, N.C. --(BUSINESS WIRE)--Jun. 1, 2021-- Precision…